In the Media Tag: Wei Li

Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer

In the Media Icon

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer.… Read More

Inaugural CORNET Awards Presented for Nine Research Initiatives

In the Media Icon

Nine research grants have been announced as the 2016 awardees for the inaugural University of Tennessee Health Science Center (UTHSC) Collaborative Research Network (CORNET) Awards. This year’s winners are: Isaac Donkor, PhD; Michio Kurosu, PhD; Ying Kong, PhD Bob Moore, PhD; Byron Jones, PhD; Megan Mulligan, PhD Detlef Heck, PhD; Francesca-Fang Liao, PhD; Anton Reiner,… Read More